|Articles|September 30, 2015

Clariant to Showcase Pharma Polymers and Packaging Solutions at CPhI Worldwide 2015

Exhibits include controlled atmosphere packaging for protection against moisture and oxygen, as well as specialty polymers and active ingredients for healthcare applications, among others.

Clariant announced that it will be at CPhI Worldwide 2015 to showcase its product offerings for the pharmaceutical market. Three business groups from the company will exhibit in Hall 7, Booth 7F28. 

  • Business Unit Industrial & Consumer Specialties will present innovative, sustainable and trend-based products to support the changing needs of the pharmaceutical market. High-purity ingredients include Polyglykol universally applicable pharmaceutical polymers, and a complete range of Macrogols with various molecular weights, all of them supported by CEP certification and DMF.

  • Clariant Healthcare Packaging manufactures controlled atmosphere packaging that helps to protect healthcare products from humidity and oxygen. Its portfolio includes industry-leading desiccant canisters and packets; tubes and desiccant stoppers; Tubairless, an innovative airless packaging system for protecting and dispensing sensitive pharmaceutical semi-solids and creams; EQ-Can and EQ-Pak humidity regulators; and more.

  • Clariant Healthcare Polymer Solutions will featuring the MEVOPUR and the REMAFIN-EP brands of color and performance master batches and compounds developed specifically for the medical device and pharmaceutical packaging sector, including new UV-blocking protection for transparent packaging, improved resistance to e-beam, gamma, X-ray sterilization, and new anti-static and anti-blocking functionality for pharmaceutical packaging films. The REMAFIN-EP range of white master batches for pharmaceutical packaging has been extended with increased regulatory support with test documentation for USP661.

Source: Clariant, Booth 7F28

 

Related to this article

Complying with International Pharmacopoeias
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Trophy and confetti on light background, top view with space for text. Victory concept | Image Credit: ©New Africa -stock.adobe.com
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.